Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

被引：33

作者：

Kuppen, Malou C. P. ^{[1
]}

Westgeest, Hans M. ^{[2
]}

van der Doelen, Maarten J. ^{[3
]}

van den Eertwegh, Alphonsus J. M. ^{[4
]}

Coenen, Jules L. L. M. ^{[5
]}

Aben, Katja K. H. ^{[6
,7
]}

van den Bergh, Alphons C. M. ^{[8
]}

Bergman, Andries M. ^{[9
]}

van den Bosch, Joan ^{[10
]}

Celik, Filiz ^{[11
]}

Hendriks, Mathijs P. ^{[12
]}

Lavalaye, Jules ^{[13
]}

van der Meer, Saskia ^{[14
]}

Polee, Marco B. ^{[15
]}

Somford, Diederik M. ^{[16
]}

van Oort, Inge M. ^{[17
]}

Uyl-de Groot, Carin A. ^{[1
]}

Gerritsen, Winald R. ^{[3
]}

机构：

[1] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Inst Med Technol Assessment, Rotterdam, Netherlands

[2] Amphia Hosp, Dept Internal Med, Breda, Netherlands

[3] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands

[4] Vrije Univ, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands

[5] Isala, Dept Oncol, Zwolle, Netherlands

[6] Radboud Univ Nijmegen, Dept Hlth Evidence, Med Ctr, Nijmegen, Netherlands

[7] Netherlands Comprehens Canc Org, Utrecht, Netherlands

[8] Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands

[9] Netherlands Canc Inst, Div Internal Med MOD & Oncogen, Antoni van Leeuwenhoek Hosp, Amsterdam, Netherlands

[10] Albert Schweitzer Ziekenhuis, Dept Internal Med, Dordrecht, Netherlands

[11] Deventer Hosp, Dept Nucl Med, Deventer, Netherlands

[12] Northwest Clin, Dept Internal Med, Alkmaar, Netherlands

[13] St Antonius Hosp, Dept Nucl Med, Nieuwegein, Netherlands

[14] Jeroen Bosch Hosp, Dept Urol, sHertogenbosch, Netherlands

[15] Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands

[16] Canisius Wilhelmina Hosp, Dept Urol, Nijmegen, Netherlands

[17] Radboud Univ Nijmegen, Dept Urol, Med Ctr, Nijmegen, Netherlands

来源：

FUTURE ONCOLOGY | 2020年 / 16卷 / 19期

关键词：

metastatic castration-resistant prostate cancer; radium-223; real-world outcomes; sequencing; skeletal-related events; survival; BONE METASTASES; DOUBLE-BLIND; THERAPY; PHASE-3; TRIAL; RECOMMENDATIONS; EXPERIENCE; EFFICACY; EVENTS; CYCLES;

D O I：

10.2217/fon-2020-0039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line >= 3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line >= 3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

引用

页码：1371 / 1384

页数：14

共 50 条

[31] Nursing Management of Patients With Castration-Resistant Prostate Cancer Undergoing Radium-223 Dichloride Treatment
Delacruz, Anthony
Arauz, Gabrielle
Curley, Tracy
Lindo, Amabella
Jensen, Trine
CLINICAL JOURNAL OF ONCOLOGY NURSING, 2015, 19 (02) : E31 - E35
[32] Lymph Node Response in a Patient With Metastatic Castration-resistant Prostate Cancer Treated With Radium-223
Poon, Darren M. C.
Wong, Kenneth C. W.
CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : E397 - E401
[33] Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer
Picciotto, Maria
Franchina, Tindara
Russo, Alessandro
Ricciardi, Giuseppina Rosaria Rita
Provazza, Giusy
Sava, Serena
Baldari, Sergio
Caffo, Orazio
Adamo, Vincenzo
EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (09) : 899 - 908
[34] Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer
Borso, Elisa
Boni, Giuseppe
Galli, Luca
Ricci, Sergio
Farnesi, Azzurra
Mazzarri, Sara
Cianci, Claudia
Mariani, Giuliano
Falcone, Alfredo
FUTURE ONCOLOGY, 2015, 11 (02) : 323 - 331
[35] Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer
Dandapani, Savita V.
Wong, Jeffrey
Twardowski, Przemyslaw
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2020, 35 (07) : 490 - 496
[36] A Case of Success: Complete Response to Radium-223 in Metastatic Castration-Resistant Prostate Cancer
Pinho, Ines Soares de
Esperanca-Martins, Miguel
Machado, Barbara
Damaso, Sara
Bras, Raquel Lopes
Cantinho, Guilhermina
Fernandes, Isabel
Costa, Luis
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (02)
[37] EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer
Poeppel, Thorsten D.
Handkiewicz-Junak, Daria
Andreeff, Michael
Becherer, Alexander
Bockisch, Andreas
Fricke, Eva
Geworski, Lilli
Heinzel, Alexander
Krause, Bernd J.
Krause, Thomas
Mitterhauser, Markus
Sonnenschein, Wilfried
Bodei, Lisa
Delgado-Bolton, Roberto C.
Gabriel, Michael
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (05) : 824 - 845
[38] RADIUM 223 FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Miranda, Jesus
Vinal, David
Pinto, Alvaro
ARCHIVOS ESPANOLES DE UROLOGIA, 2019, 72 (05): : 500 - 507
[39] Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223
Rodriguez-Vida, A.
Torregrosa, M. D.
Pinto, A.
Climent, M. A.
Olmos, D.
Carles, J.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (06) : 679 - 686
[40] Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer
Buroni, Federica Eleonora
Persico, Marco Giovanni
Pasi, Francesca
Lodola, Lorenzo
Nano, Rosanna
Aprile, Carlo
ANTICANCER RESEARCH, 2016, 36 (11) : 5719 - 5730

← 1 2 3 4 5 →